311 related articles for article (PubMed ID: 29159801)
1. Real-life clinical use of natalizumab and fingolimod in Austria.
Guger M; Enzinger C; Leutmezer F; Kraus J; Kalcher S; Kvas E; Berger T
Acta Neurol Scand; 2018 Feb; 137(2):181-187. PubMed ID: 29159801
[TBL] [Abstract][Full Text] [Related]
2. Real-life use of oral disease-modifying treatments in Austria.
Guger M; Enzinger C; Leutmezer F; Kraus J; Kalcher S; Kvas E; Berger T;
Acta Neurol Scand; 2019 Jul; 140(1):32-39. PubMed ID: 30958901
[TBL] [Abstract][Full Text] [Related]
3. Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis.
Iaffaldano P; Lucisano G; Pozzilli C; Brescia Morra V; Ghezzi A; Millefiorini E; Patti F; Lugaresi A; Zimatore GB; Marrosu MG; Amato MP; Bertolotto A; Bergamaschi R; Granella F; Coniglio G; Tedeschi G; Sola P; Lus G; Ferrò MT; Iuliano G; Corea F; Protti A; Cavalla P; Guareschi A; Rodegher M; Paolicelli D; Tortorella C; Lepore V; Prosperini L; Saccà F; Baroncini D; Comi G; Trojano M;
Brain; 2015 Nov; 138(Pt 11):3275-86. PubMed ID: 26362907
[TBL] [Abstract][Full Text] [Related]
4. Switching from natalizumab to fingolimod treatment in multiple sclerosis: real life data from the Austrian MS Treatment Registry.
Guger M; Enzinger C; Leutmezer F; Kraus J; Kalcher S; Kvas E; Berger T;
J Neurol; 2019 Nov; 266(11):2672-2677. PubMed ID: 31312958
[TBL] [Abstract][Full Text] [Related]
5. Comparative analysis of natalizumab versus fingolimod as second-line treatment in relapsing-remitting multiple sclerosis.
Lorscheider J; Benkert P; Lienert C; Hänni P; Derfuss T; Kuhle J; Kappos L; Yaldizli Ö
Mult Scler; 2018 May; 24(6):777-785. PubMed ID: 29685071
[TBL] [Abstract][Full Text] [Related]
6. A longitudinal real-life comparison study of natalizumab and fingolimod.
Lanzillo R; Carotenuto A; Moccia M; Saccà F; Russo CV; Massarelli M; De Rosa A; Brescia Morra V
Acta Neurol Scand; 2017 Sep; 136(3):217-222. PubMed ID: 27976804
[TBL] [Abstract][Full Text] [Related]
7. A comparison of multiple sclerosis clinical disease activity between patients treated with natalizumab and fingolimod.
Koch-Henriksen N; Magyari M; Sellebjerg F; Soelberg Sørensen P
Mult Scler; 2017 Feb; 23(2):234-241. PubMed ID: 27055806
[TBL] [Abstract][Full Text] [Related]
8. The comparative effectiveness of fingolimod, natalizumab, and ocrelizumab in relapsing-remitting multiple sclerosis.
Boz C; Ozakbas S; Terzi M; Karabudak R; Sevim S; Turkoglu R; Soysal A; Balcı BP; Efendi H; Turan ÖF; Yüceyar N; Yetkin MF; Karahan SZ; Demirkıran M; Guler S; Agan K; Kıylıoğlu N; Baba C; Tuncer A; Köseoğlu M
Neurol Sci; 2023 Jun; 44(6):2121-2129. PubMed ID: 36689010
[TBL] [Abstract][Full Text] [Related]
9. Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies.
Baroncini D; Ghezzi A; Annovazzi PO; Colombo B; Martinelli V; Minonzio G; Moiola L; Rodegher M; Zaffaroni M; Comi G
Mult Scler; 2016 Sep; 22(10):1315-26. PubMed ID: 27230789
[TBL] [Abstract][Full Text] [Related]
10. Second-line therapy with fingolimod for relapsing-remitting multiple sclerosis in clinical practice: the effect of previous exposure to natalizumab.
Bianco A; Patanella AK; Nociti V; Marti A; Frisullo G; Plantone D; De Fino C; Fetta A; Batocchi AP; Rossini PM; Mirabella M
Eur Neurol; 2015; 73(1-2):57-65. PubMed ID: 25402749
[TBL] [Abstract][Full Text] [Related]
11. Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in rapidly evolving severe relapsing-remitting multiple sclerosis in the United Kingdom.
Spelman T; Herring WL; Acosta C; Hyde R; Jokubaitis VG; Pucci E; Lugaresi A; Laureys G; Havrdova EK; Horakova D; Izquierdo G; Eichau S; Ozakbas S; Alroughani R; Kalincik T; Duquette P; Girard M; Petersen T; Patti F; Csepany T; Granella F; Grand'Maison F; Ferraro D; Karabudak R; Jose Sa M; Trojano M; van Pesch V; Van Wijmeersch B; Cartechini E; McCombe P; Gerlach O; Spitaleri D; Rozsa C; Hodgkinson S; Bergamaschi R; Gouider R; Soysal A; Castillo-Triviño ; Prevost J; Garber J; de Gans K; Ampapa R; Simo M; Sanchez-Menoyo JL; Iuliano G; Sas A; van der Walt A; John N; Gray O; Hughes S; De Luca G; Onofrj M; Buzzard K; Skibina O; Terzi M; Slee M; Solaro C; Oreja-Guevara ; Ramo-Tello C; Fragoso Y; Shaygannejad V; Moore F; Rajda C; Aguera Morales E; Butzkueven H
J Med Econ; 2024; 27(1):109-125. PubMed ID: 38085684
[TBL] [Abstract][Full Text] [Related]
12. Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts.
Sharmin S; Lefort M; Andersen JB; Leray E; Horakova D; Havrdova EK; Alroughani R; Izquierdo G; Ozakbas S; Patti F; Onofrj M; Lugaresi A; Terzi M; Grammond P; Grand'Maison F; Yamout B; Prat A; Girard M; Duquette P; Boz C; Trojano M; McCombe P; Slee M; Lechner-Scott J; Turkoglu R; Sola P; Ferraro D; Granella F; Prevost J; Maimone D; Skibina O; Buzzard K; Van der Walt A; Van Wijmeersch B; Csepany T; Spitaleri D; Vucic S; Casey R; Debouverie M; Edan G; Ciron J; Ruet A; De Sèze J; Maillart E; Zephir H; Labauge P; Defer G; Lebrun-Frénay C; Moreau T; Berger E; Clavelou P; Pelletier J; Stankoff B; Gout O; Thouvenot E; Heinzlef O; Al-Khedr A; Bourre B; Casez O; Cabre P; Montcuquet A; Wahab A; Camdessanché JP; Maurousset A; Patry I; Hankiewicz K; Pottier C; Maubeuge N; Labeyrie C; Nifle C; Laplaud D; Koch-Henriksen N; Sellebjerg FT; Soerensen PS; Pfleger CC; Rasmussen PV; Jensen MB; Frederiksen JL; Bramow S; Mathiesen HK; Schreiber KI; Magyari M; Vukusic S; Butzkueven H; Kalincik T;
CNS Drugs; 2021 Nov; 35(11):1217-1232. PubMed ID: 34536228
[TBL] [Abstract][Full Text] [Related]
13. Systematic literature review and network meta-analysis in highly active relapsing-remitting multiple sclerosis and rapidly evolving severe multiple sclerosis.
Huisman E; Papadimitropoulou K; Jarrett J; Bending M; Firth Z; Allen F; Adlard N
BMJ Open; 2017 Mar; 7(3):e013430. PubMed ID: 28283486
[TBL] [Abstract][Full Text] [Related]
14. The effectiveness of fingolimod in a Portuguese real-world population.
Correia I; Batista S; Marques IB; Sousa M; Ferreira R; Nunes C; Macário MC; Sousa L
Mult Scler Relat Disord; 2016 Mar; 6():41-48. PubMed ID: 27063621
[TBL] [Abstract][Full Text] [Related]
15. Annualized hospitalization rate with natalizumab vs fingolimod in second-line treatment for RRMS in the public healthcare system in Brazil: A claim database approach.
Julian GS; Rosim RP; Carneseca EC; Rigolon J
PLoS One; 2020; 15(3):e0229768. PubMed ID: 32119696
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of Fingolimod versus Natalizumab as Second-Line Therapy for Relapsing-Remitting Multiple Sclerosis in Spain: Second-Line GATE Study.
Meca-Lallana J; Ayuso T; Martínez-Yelamos S; Durán C; Contreras Martín Y; Herrera Navarro N; Pérez Sempere A; Álvarez-Cermeño JC; Millán Pascual J; Meca-Lallana V; Romero Sevilla R; Ricart J
Eur Neurol; 2020; 83(1):25-33. PubMed ID: 32187609
[TBL] [Abstract][Full Text] [Related]
17. Oral therapies for treatment of relapsing-remitting multiple sclerosis in Austria: a 2-year comparison using an inverse probability weighting method.
Guger M; Enzinger C; Leutmezer F; Kraus J; Kalcher S; Kvas E; Berger T;
J Neurol; 2020 Jul; 267(7):2090-2100. PubMed ID: 32246251
[TBL] [Abstract][Full Text] [Related]
18. Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis.
Kalincik T; Horakova D; Spelman T; Jokubaitis V; Trojano M; Lugaresi A; Izquierdo G; Rozsa C; Grammond P; Alroughani R; Duquette P; Girard M; Pucci E; Lechner-Scott J; Slee M; Fernandez-Bolanos R; Grand'Maison F; Hupperts R; Verheul F; Hodgkinson S; Oreja-Guevara C; Spitaleri D; Barnett M; Terzi M; Bergamaschi R; McCombe P; Sanchez-Menoyo J; Simo M; Csepany T; Rum G; Boz C; Havrdova E; Butzkueven H;
Ann Neurol; 2015 Mar; 77(3):425-35. PubMed ID: 25546031
[TBL] [Abstract][Full Text] [Related]
19. Effects of horizontal versus vertical switching of disease-modifying treatment after platform drugs on disease activity in patients with relapsing-remitting multiple sclerosis in Austria.
Guger M; Enzinger C; Leutmezer F; Di Pauli F; Kraus J; Kalcher S; Kvas E; Berger T;
J Neurol; 2023 Jun; 270(6):3103-3111. PubMed ID: 36862148
[TBL] [Abstract][Full Text] [Related]
20. Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study.
Kalincik T; Brown JWL; Robertson N; Willis M; Scolding N; Rice CM; Wilkins A; Pearson O; Ziemssen T; Hutchinson M; McGuigan C; Jokubaitis V; Spelman T; Horakova D; Havrdova E; Trojano M; Izquierdo G; Lugaresi A; Prat A; Girard M; Duquette P; Grammond P; Alroughani R; Pucci E; Sola P; Hupperts R; Lechner-Scott J; Terzi M; Van Pesch V; Rozsa C; Grand'Maison F; Boz C; Granella F; Slee M; Spitaleri D; Olascoaga J; Bergamaschi R; Verheul F; Vucic S; McCombe P; Hodgkinson S; Sanchez-Menoyo JL; Ampapa R; Simo M; Csepany T; Ramo C; Cristiano E; Barnett M; Butzkueven H; Coles A;
Lancet Neurol; 2017 Apr; 16(4):271-281. PubMed ID: 28209331
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
